Efficacy and safety of tafluprost in normal-tension glaucoma with intraocular pressure of 16 mmHg or less.

Abstract

PURPOSE:

To evaluate the intraocular pressure (IOP)-reducing effects and safety of 0.0015% tafluprost ophthalmic solution (tafluprost) in normal-tension glaucoma (NTG) patients with an IOP of 16 mmHg or less.

METHODS:

NTG patients with a baseline IOP of 16 mmHg or less were enrolled for a one-eye study in which tafluprost was applied once daily for 12 weeks. The presence of adverse drug reactions and the cumulative incidence of adverse events were also investigated.

RESULTS:

Among the 44 enrolled patients, 41/44 (93.2%) eyes completed the study. The baseline IOP was 13.2 ± 1.3 mmHg in the study eyes and 13.0 ± 1.3 mmHg in the fellow eyes, which was not statistically significant (P = 0.9173, Student's t test). The values obtained for IOP in the study eyes versus fellow eyes were 10.2 ± 1.6 versus 12.1 ± 1.5 mmHg at week 12. The IOP difference between the study eyes and the fellow eyes was statistically significant (P < 0.0001, Student's t test). The cumulative incidence of adverse events was 58.5% by week 12. Ocular itching was the most frequently observed adverse event (29.3%). All adverse events were clinically tolerable.

CONCLUSIONS:

Tafluprost induced significant IOP reductions in NTG patients with a baseline IOP of 16 mmHg or less without raising any safety concerns.

• Authors: Tadashi Nakano, Keiji Yoshikawa, Tairo Kimura, Hirotaka Suzumura, Mami Nanno, Takahiko Noro
• Journal: Japanese journal of ophthalmology (Jpn J Ophthalmol) Vol. 55 Issue 6 Pg. 605-13 (Nov 2011) ISSN: 1613-2246 [Electronic] Japan
• PMID: 21874307 (Publication Type: Journal Article, Multicenter Study)

Chemical References

• Antihypertensive Agents
• Ophthalmic Solutions
• Prostaglandins F
• tafluprost

Topics

• Antihypertensive Agents (adverse effects, therapeutic use)
• Female
• Follow-Up Studies
• Humans
• Intraocular Pressure (drug effects)
• Low Tension Glaucoma (drug therapy, physiopathology)
• Male
• Middle Aged
• Ophthalmic Solutions (adverse effects, therapeutic use)
• Prospective Studies
• Prostaglandins F (adverse effects, therapeutic use)
• Tonometry, Ocular
• Treatment Outcome
• Visual Acuity (physiology)